90484-39-2

Basic information

• Product Name: (4-bromo-phenylhydrazono)-malonic acid
• Synonyms: (4-bromo-phenylhydrazono)-malonic acid
• CAS NO: 90484-39-2
• Molecular Weight: 287.07
• Mol File: 90484-39-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (4-bromo-phenylhydrazono)-malonic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (4-bromo-phenylhydrazono)-malonic acid(90484-39-2)
• EPA Substance Registry System: (4-bromo-phenylhydrazono)-malonic acid(90484-39-2)

Safety Data

• Hazardous Substances Data: 90484-39-2(Hazardous Substances Data)

Upstream product

• 473-90-5 acetonedicarboxylic acid 
• 589-21-9 (4-bromophenyl)hydrazine 
• 624-19-1 4-bromoaniline hydrochloride 
• 13631-76-0 (4-bromo-phenylhydrazono)-malonic acid diethyl ester 

Downstream Products

• 876-88-0 6-bromo-1H-cinnolin-4-one 
• 90271-82-2 (4-bromo-phenylhydrazono)-malonyl chloride 

Relevant articles and documents

Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors

We report the discovery of a novel series of 3-cinnoline carboxamides as highly potent and selective ataxia telangiectasia mutated (ATM) kinase inhibitors. Optimization of this series focusing on potency and physicochemical properties (especially permeability) led to the identification of compound 21, a highly potent ATM inhibitor (ATM cell IC50 0.0028 μM) with excellent kinase selectivity and favorable physicochemical and pharmacokinetics properties. In vivo, 21 in combination with irinotecan showed tumor regression in the SW620 colorectal tumor xenograft model, superior inhibition to irinotecan alone. Compound 21 was selected for preclinical evaluation alongside AZD0156.

CINNOLIN-4-AMINE COMPOUNDS AND THEIR USE IN TREATING CANCER

This specification generally relates to compounds of Formula (I). And pharmaceutically acceptable salts thereof, where R1, R2 and R3 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent ATM kinase mediated disease, including cancer. The specification further relates to crystalline forms of compounds of Formula (I) and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts thereof; kits comprising such compounds and salts thereof; methods of manufacture of such compounds and salts thereof; intermediates useful in the manufacture of such compounds and salts thereof; and to methods of treating ATM kinase mediated disease, including cancer, using compounds of Formula (I) and salts thereof alone or in combination with other therapies.